METHODS: A cost-benefit analysis (CBA) was completed to compare the projected costs and benefits associated with continuing to run the NJPMP. Data was collected through the NJ Division of Consumer Affairs, Office of the Attorney General, and other state divisions. The value of lives saved through non-fatal hospitalizations and opioid related deaths were calculated by multiplying the average difference between the projected deaths with and without the NJPMP by the value of a statistical life. Then, the costs of running the NJPMP were calculated using personnel, software, and other related costs. The CBA ratios for the years 2012-2019 were calculated.

RESULTS: The CBA ratios for the years 2012-2019 ranged from 5.71 to 6.55, indicating that for every dollar invested into the NJPMP, $5.71 to $6.55 was saved annually with respect to the value of lives saved from fatal and non-fatal opioid overdoses. There was a decline in the CBA ratio when fentanyl related overdoses were incorporated, decreasing from 6.55 in 2016 to 6.31 in 2019.

CONCLUSIONS: The positive CBA ratio shows that the NJPMP serves a financial benefit to the payers of the program and that it benefits society. However, the decreasing trend in the ratio suggests that this may not be the case in the long-term. Unfortunately, the lack of impact on illicitly distributed fentanyl may limit the effectiveness of the NJPMP.